iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis

<p>Abstract</p> <p>Background</p> <p>Pharmacological interactions are useful for understanding ligand binding mechanisms of a therapeutic target. These interactions are often inferred from a set of active compounds that were acquired experimentally. Moreover, most docking programs loosely coupled the stages (binding-site and ligand preparations, virtual screening, and post-screening analysis) of structure-based virtual screening (VS). An integrated VS environment, which provides the friendly interface to seamlessly combine these VS stages and to identify the pharmacological interactions directly from screening compounds, is valuable for drug discovery.</p> <p>Results</p> <p>We developed an easy-to-use graphic environment, <it>i</it>GEMDOCK, integrating VS stages (from preparations to post-screening analysis). For post-screening analysis, <it>i</it>GEMDOCK provides biological insights by deriving the pharmacological interactions from screening compounds without relying on the experimental data of active compounds. The pharmacological interactions represent conserved interacting residues, which often form binding pockets with specific physico-chemical properties, to play the essential functions of a target protein. Our experimental results show that the pharmacological interactions derived by <it>i</it>GEMDOCK are often hot spots involving in the biological functions. In addition, <it>i</it>GEMDOCK provides the visualizations of the protein-compound interaction profiles and the hierarchical clustering dendrogram of the compounds for post-screening analysis.</p> <p>Conclusions</p> <p>We have developed <it>i</it>GEMDOCK to facilitate steps from preparations of target proteins and ligand libraries toward post-screening analysis. <it>i</it>GEMDOCK is especially useful for post-screening analysis and inferring pharmacological interactions from screening compounds. We believe that <it>i</it>GEMDOCK is useful for understanding the ligand binding mechanisms and discovering lead compounds. <it>i</it>GEMDOCK is available at <url>http://gemdock.life.nctu.edu.tw/dock/igemdock.php</url>.</p

SiMMap: a web server for inferring site-moiety map to recognize interaction preferences between protein pockets and compound moieties

The protein–ligand interacting mechanism is essential to biological processes and drug discovery. The SiMMap server statistically derives site-moiety map with several anchors, which describe the relationship between the moiety preferences and physico-chemical properties of the binding site, from the interaction profiles between query target protein and its docked (or co-crystallized) compounds. Each anchor includes three basic elements: a binding pocket with conserved interacting residues, the moiety composition of query compounds and pocket–moiety interaction type (electrostatic, hydrogen bonding or van der Waals). We provide initial validation of the site-moiety map on three targets, thymidine kinase, and estrogen receptors of antagonists and agonists. Experimental results show that an anchor is often a hot spot and the site-moiety map can help to assemble potential leads by optimal steric, hydrogen bonding and electronic moieties. When a compound highly agrees with anchors of site-moiety map, this compound often activates or inhibits the target protein. We believe that the site-moiety map is useful for drug discovery and understanding biological mechanisms. The SiMMap web server is available at http://simfam.life.nctu.edu.tw/

Applications of Support Vector Machines as a Robust tool in High Throughput Virtual Screening

Chemical space is enormously huge but not all of it is pertinent for the drug designing. Virtual screening methods act as knowledge-based filters to discover the coveted novel lead molecules possessing desired pharmacological properties. Support Vector Machines (SVM) is a reliable virtual screening tool for prioritizing molecules with the required biological activity and minimum toxicity. It has to its credit inherent advantages such as support for noisy data mainly coming from varied high-throughput biological assays, high sensitivity, specificity, prediction accuracy and reduction in false positives. SVM-based classification methods can efficiently discriminate inhibitors from non-inhibitors, actives from inactives, toxic from non-toxic and promiscuous from non-promiscuous molecules. As the principles of drug design are also applicable for agrochemicals, SVM methods are being applied for virtual screening for pesticides too. The current review discusses the basic kernels and models used for binary discrimination and also features used for developing SVM-based scoring functions, which will enhance our understanding of molecular interactions. SVM modeling has also been compared by many researchers with other statistical methods such as Artificial Neural Networks, k-nearest neighbour (kNN), decision trees, partial least squares, etc. Such studies have also been discussed in this review. Moreover, a case study involving the use of SVM method for screening molecules for cancer therapy has been carried out and the preliminary results presented here indicate that the SVM is an excellent classifier for screening the molecules

Mind the Gap - Deciphering GPCR Pharmacology Using 3D Pharmacophores and Artificial Intelligence

G protein-coupled receptors (GPCRs) are amongst the most pharmaceutically relevant and well-studied protein targets, yet unanswered questions in the field leave significant gaps in our understanding of their nuanced structure and function. Three-dimensional pharmacophore models are powerful computational tools in in silico drug discovery, presenting myriad opportunities for the integration of GPCR structural biology and cheminformatics. This review highlights success stories in the application of 3D pharmacophore modeling to de novo drug design, the discovery of biased and allosteric ligands, scaffold hopping, QSAR analysis, hit-to-lead optimization, GPCR de-orphanization, mechanistic understanding of GPCR pharmacology and the elucidation of ligand–receptor interactions. Furthermore, advances in the incorporation of dynamics and machine learning are highlighted. The review will analyze challenges in the field of GPCR drug discovery, detailing how 3D pharmacophore modeling can be used to address them. Finally, we will present opportunities afforded by 3D pharmacophore modeling in the advancement of our understanding and targeting of GPCRs

Designing the molecular future

Approximately 25years ago the first computer applications were conceived for the purpose of automated ‘de novo' drug design, prominent pioneering tools being ALADDIN, CAVEAT, GENOA, and DYLOMMS. Many of these early concepts were enabled by innovative techniques for ligand-receptor interaction modeling like GRID, MCSS, DOCK, and CoMFA, which still provide the theoretical framework for several more recently developed molecular design algorithms. After a first wave of software tools and groundbreaking applications in the 1990s—expressly GROW, GrowMol, LEGEND, and LUDI representing some of the key players—we are currently witnessing a renewed strong interest in this field. Innovative ideas for both receptor and ligand-based drug design have recently been published. We here provide a personal perspective on the evolution of de novo design, highlighting some of the historic achievements as well as possible future developments of this exciting field of research, which combines multiple scientific disciplines and is, like few other areas in chemistry, subject to continuous enthusiastic discussion and compassionate disput

Using Protein Homology Models for Structure-Based Studies: Approaches to Model Refinement

Homology modeling is a computational methodology to assign a 3-D structure to a target protein when experimental data are not available. The methodology uses another protein with a known structure that shares some sequence identity with the target as a template. The crudest approach is to thread the target protein backbone atoms over the backbone atoms of the template protein, but necessary refinement methods are needed to produce realistic models. In this mini-review anchored within the scope of drug design, we show the validity of using homology models of proteins in the discovery of binders for potential therapeutic targets. We also report several different approaches to homology model refinement, going from very simple to the most elaborate. Results show that refinement approaches are system dependent and that more elaborate methodologies do not always correlate with better performances from built homology models

Entwicklung einer computergestützten Methode zum reaktionsbasierten De-Novo-Design wirkstoffartiger Verbindungen

A new method for computer-based de novo design of drug candidate structures is proposed. DOGS (Design of Genuine Structures) features a ligand-based strategy to suggest new molecular structures. The quality of designed compounds is assessed by a graph kernel method measuring the distance of designed molecules to a known reference ligand. Two graph representations of molecules (molecular graph and reduced graph) are implemented to feature different levels of abstraction from the molecular structure. A fully deterministic construction procedure explicitly designed to facilitate synthesizability of proposed structures is realized: DOGS uses readily available synthesis building blocks and established reaction schemes to assemble new molecules. This approach enables the software to propose not only the final compounds, but also to give suggestions for synthesis routes to generate them at the bench. The set of synthesis schemes comprises about 83 chemical reactions. Special focus was put on ring closure reactions forming drug-like substructures. The library of building blocks consists of about 25,000 readily available synthesis building blocks. DOGS builds up new structures in a stepwise process. Each virtual synthesis step adds a fragment to the growing molecule until a stop criterion (upper threshold for molecular mass or number of synthesis steps) is fulfilled. In a theoretical evaluation, a set of ~1,800 molecules proposed by DOGS is analyzed for critical properties of de novo designed compounds. The software is able to suggest drug-like molecules (79% violate less than two of Lipinski’s ‘rule of five’). In addition, a trained classifier for drug-likeness assigns a score >0.8 to 51% of the designed molecules (with 1.0 being the top score). In addition, most of the DOGS molecules are deemed to be synthesizable by a retro-synthesis descriptor (77% of molecules score in the top 10% of the decriptor’s value range). Calculated logP(o/w) values of constructed molecules resemble a unimodal distribution centred close to the mean of logP(o/w) values calculated for the reference compounds. A structural analysis of selected designs reveals that DOGS is capable of constructing molecules reflecting the overall topological arrangement of pharmacophoric features found in the reference ligands. At the same time, the DOGS designs represent innovative compounds being structurally distinct from the references. Synthesis routes for these examples are short and seem feasible in most cases. Some reaction steps might need modification by using protecting groups to avoid unwanted side reactions. Plausible bioisosters for known privileged fragments addressing the S1 pocket of trypsin were proposed by DOGS in a case study. Three of them can be found in known trypsin inhibitors as S1-adressing side chains. The software was also tested in two prospective case studies to design bioactive compounds. DOGS was applied to design ligands for human gamma-secretase and human histamine receptor subtype 4 (hH4R). Two selected designs for gamma-secretase were readily synthesizable as suggested by the software in one-step reactions. Both compounds represent inverse modulators of the target molecule. In a second case study, a ligand candidate selected for hH4R was synthesized exactly following the three-step synthesis plan suggested by DOGS. This compound showed low activity on the target structure. The concept of DOGS is able to deliver synthesizable and bioactive compounds. Suggested synthesis plans of selected compounds were readily pursuable. DOGS can therefore serve as a valuable idea generator for the design of new pharmacological active compounds.Im Rahmen der vorliegenden Arbeit wird eine neue Methode zum computergestützten de novo Design von wirkstoffartigen Molekülen vorgestellt. Ziel ist es, automatisiert und zielgerichtet neuartige Moleküle mit biologischer Aktivität zu entwerfen. Das entwickelte Programm DOGS (Design of Genuine Structures) schlägt zusätzlich zu den chemischen Verbindungen mögliche Strategien zu deren Synthese vor. Ein vollständig deterministischer Konstruktionsalgorithmus verwendet verfügbare Synthesebausteine und etablierte chemische Reaktionen zum Aufbau der neuen Moleküle. Die Bibliothek der Synthesebausteine umfasst etwa 25.000 Moleküle mit einer molekularen Masse zwischen 30 und 300 Da. Die Sammlung der Reaktionen zur Verknüpfung der Bausteine besteht aus 83 literaturbeschriebenen chemischen Reaktionen. Ein Großteil stellt Syntheseschritte zur Generierung neuer Ringsysteme dar. DOGS baut neue Moleküle schrittweise auf: In jedem virtuellen Syntheseschritt wird ein neues Fragment an das wachsende Molekül angefügt, bis eines der Stoppkriterien (Überschreitung einer maximalen molekulare Masse oder Anzahl Syntheseschritte) erfüllt ist. Zur Bewertung der Qualität der Zischen- und Endprodukte wird eine ligandenbasierte Strategie verwendet. Die entstehenden Moleküle werden mit einem bekannten Referenzliganden verglichen, welcher die gewünschte biologische Aktivität aufweist. Das Verfahren zielt dabei auf die Maximierung der Ähnlichkeit der neu konstruierten Moleküle zur Referenz ab. Eine Graphkernmethode berechnet die Ähnlichkeit zum Referenzliganden anhand des Vergleichs ihrer zweidimensionalen molekularen Struktur. In einer theoretischen Auswertung des Programms werden ca. 1.800 generierte potentielle Trypsin-Inhibitoren hinsichtlich solcher Eigenschaften analysiert, welche für neu entworfene Verbindungen kritisch sind: DOGS ist in der Lage wirkstoffartige Moleküle zu entwerfen (79% verletzen weniger als zwei von Lipinskis 'rule of five' Kriterien zur Abschätzung der oralen Bioverfügbarkeit). Zusätzlich wurde die Wirkstoffartigkeit der DOGS-Moleküle durch einen trainierten Klassifizieralgorithmus bewertet. Hierbei erhielten 51% der Verbindungen einen Wert in den oberen 20% des Wertebereichs des Klassifizierers. Weiterhin wird die synthetische Zugänglichkeit für den Großteil der computergenerierten Moleküle als hoch eingeschätzt (77% erhalten einen Wert in den oberen 10% des Wertebereichs eines Deskriptors zur Abschätzung der Synthetisierbarkeit). Die berechneten logP(o/w) Werte der konstruierten Moleküle entsprechen in ihrer Verteilung denen der Referenzliganden. Die Untersuchung der vorgeschlagenen Trypsin-Inhibitoren auf Bioisostere zur Adressierung der S1-Bindetasche zeigt, dass hierfür plausible Vorschläge von DOGS generiert werden. Der Großteil ist potentiell in der Lage eine kritische ladungsvermittelte Interaktion mit dem Protein in der S1-Bindetasche einzugehen. Unter den Vorschlägen befinden sich unter anderem auch drei Seitenketten, für die Interaktionen mit der S1-Bindetasche von Trypsin experimentell bestätigt sind. Eine Analyse ausgewählter Beispiele aus verschiedenen Läufen zum Ligandenentwurf für unterschiedliche biologische Zielmoleküle zeigt, dass das Programm in der Lage ist, die generelle topologische Anordnung potentieller Interaktionspunkte der Referenzliganden in den neu erzeugten Molekülen beizubehalten. Gleichzeitig sind diese Moleküle strukturell verschieden im Vergleich zu den Referenzliganden. Die generierten Synthesewege sind kurz und erscheinen in den meisten Fällen plausibel. Für einige der Syntheseschritte wird bei der praktischen Umsetzung der ergänzende Einsatz von Schutzgruppen notwendig sein, um unerwünschte Nebenreaktionen zu vermeiden. Die Software wurde zusätzlich zu den theoretischen Analysen in prospektiven Studien zum Ligandenentwurf praktisch evaluiert. Hierzu wurde DOGS zur Generierung von Liganden des humanen Histaminrezeptors 4 (hH4R) sowie der humanen gamma-Sekretase eingesetzt. Für hH4R wurde einer der entworfenen potentiellen Liganden synthetisiert, wobei der vorgeschlagene Syntheseweg exakt nachvollzogen werden konnte. Der Ligand weist eine geringfügige Affinität zum Histaminrezeptor auf. Für die gamma-Sekretase wurden zwei der entworfenen Moleküle zur Synthese und Testung ausgewählt. In beiden Fällen konnte auch hier die von DOGS vorgeschlagene Synthesestrategie nachvollzogen werden. Anschließende in vitro Analysen wiesen beide Verbindungen als inverse Modulatoren der gamma-Sekretase aus. Das Konstruktionskonzept von DOGS ist in der Lage, bioaktive Substanzen vorzuschlagen. Diese sind synthetisch zugänglich und können nach der vorgeschlagenen Strategie synthetisiert werden. Somit kann das Programm als Ideengenerator für den Entwurf neuer bioaktiver Moleküle dienen